Sensome

Sensome, a clinical-stage medtech company, was co-founded in 2014 by Franz Bozsak and Abdul Barakat. The company's origins are rooted in a decade of academic research in biomechanics and micro-acoustics, which led to the development of its proprietary technology.

Sensome's core offering is a sensor-powered guidewire designed to assist in the treatment of ischemic stroke. This technology, known as the Clotild Smart Guidewire System, integrates a micro-sensor at the tip of a neurovascular guidewire. This sensor, coupled with predictive analytics, provides physicians with real-time information on the composition of a blood clot, such as whether it is red-blood-cell-rich or fibrin-rich. This information is critical for making informed decisions during mechanical thrombectomy procedures, as the type of clot determines the most effective removal strategy. The system aims to improve the revascularization success rate on the first attempt, thereby enhancing patient outcomes.

The company's business model revolves around the development and commercialization of this smart guidewire system. Its primary market is the neurovascular field, specifically hospitals and clinics that perform ischemic stroke interventions. By providing a tool that can significantly improve the efficacy of these procedures, Sensome aims to become an indispensable part of the stroke treatment workflow.

Keywords: medtech, neurovascular, ischemic stroke, guidewire, sensor technology, clot characterization, mechanical thrombectomy, medical devices, clinical-stage, predictive analytics